Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actavis And Valeant Now Squaring Off For IBS Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Viberzi and Xifaxan share an indication and an approval date, but not much else.

You may also be interested in...



Valeant Backs Strategy With Solid Deal Record

Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.

Keeping Track: New Drugs For IBS, LAM; New NDAs for HCV and Hyperkalemia

The latest drug development news and highlights from our FDA Performance Tracker.

Capital Allocation In The Age Of Shareholder Activism

Maybe no company is safe from activists, but there are protective measures that managers and boards can take. What biopharmas can learn from Valeant Pharmaceuticals and Pershing Square’s pursuit of Allergan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel